{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T13:43:42Z","timestamp":1789911822820,"version":"4.0.1"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2017,8,29]],"date-time":"2017-08-29T00:00:00Z","timestamp":1503964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0183232","type":"journal-article","created":{"date-parts":[[2017,8,29]],"date-time":"2017-08-29T13:33:50Z","timestamp":1504013630000},"page":"e0183232","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Continuum of hepatitis C care in France: A 20-year cohort study"],"prefix":"10.1371","volume":"12","author":[{"given":"Coralie","family":"Hermetet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Gaudy-Graffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Bacq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Royer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Gaborit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"D\u2019Alteroche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Claude","family":"Desenclos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Roingeard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7934-8912","authenticated-orcid":true,"given":"Leslie","family":"Grammatico-Guillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,8,29]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S1473-3099(05)70216-4","article-title":"Global epidemiology of hepatitis C virus infection","volume":"5","author":"CW Shepard","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1002\/hep.1840360707","article-title":"Fibrosis and disease progression in hepatitis C","volume":"36","author":"P Marcellin","year":"2002","journal-title":"Hepatology"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"47","DOI":"10.7150\/ijms.3.47","article-title":"The natural history of hepatitis C virus (HCV) infection","volume":"3","author":"SL Chen","year":"2006","journal-title":"Int J Med Sci"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2893.2009.01196.x","article-title":"The impact of the prevention programme of hepatitis C over more than a decade: the French experience","volume":"17","author":"E Delarocque-Astagneau","year":"2010","journal-title":"J Viral Hepat"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1136\/gut.52.12.1784","article-title":"Treatment of hepatitis C. The 2002 French consensus","volume":"52","author":"D Dhumeaux","year":"2003","journal-title":"Gut"},{"key":"ref6","first-page":"1","article-title":"Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945\u20131965","volume":"61","author":"BD Smith","year":"2012","journal-title":"MMWR Recomm Rep"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/hep.27584","article-title":"The continuum of hepatitis C testing and care","volume":"61","author":"K Viner","year":"2015","journal-title":"Hepatology"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1002\/hep.510250630","article-title":"Hepatitis C in a French population-based survey, 1994: seroprevalence, frequency of viremia, genotype distribution, and risk factors. The Collaborative Study Group","volume":"25","author":"F Dubois","year":"1997","journal-title":"Hepatology"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/jmv.21734","article-title":"Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors","volume":"82","author":"C Meffre","year":"2010","journal-title":"J Med Virol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1038\/474S1a","article-title":"Hepatitis C","volume":"474","author":"H Brody","year":"2011","journal-title":"Nature"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","article-title":"Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence","volume":"57","author":"K Mohd Hanafiah","year":"2013","journal-title":"Hepatology"},{"key":"ref12","article-title":"Treatment of hepatitis C: Perspectives","author":"S Pol","year":"2014","journal-title":"Med Mal Infect"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1002\/hep.26194","article-title":"Hepatitis C screening: getting it right","volume":"57","author":"BR Edlin","year":"2013","journal-title":"Hepatology"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jhep.2007.09.010","article-title":"Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption","volume":"48","author":"P Marcellin","year":"2008","journal-title":"J Hepatol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.dld.2010.12.004","article-title":"Recommendations for the prevention, diagnosis, and treatment of chronic hepatitis B and C in special population groups (migrants, intravenous drug users and prison inmates)","volume":"43","author":"PL Almasio","year":"2011","journal-title":"Dig Liver Dis"},{"issue":"Suppl 5","key":"ref16","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.1016\/j.dld.2014.09.023","article-title":"Epidemiology of hepatitis C in Europe","volume":"46","author":"F Negro","year":"2014","journal-title":"Dig Liver Dis"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0140-6736(13)62121-2","article-title":"Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial","volume":"383","author":"E Lawitz","year":"2014","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/hep.27880","article-title":"Direct-acting antiviral drug approvals for treatment of chronic hepatitis C virus infection: Scientific and regulatory approaches to clinical trial designs","volume":"62","author":"P Mishra","year":"2015","journal-title":"Hepatology"},{"key":"ref19","first-page":"2367","article-title":"Changing the face of hepatitis C management\u2014the design and development of sofosbuvir","volume":"9","author":"BC Noell","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"806","DOI":"10.4254\/wjh.v7.i5.806","article-title":"Impact of all oral anti-hepatitis C virus therapy: A meta-analysis","volume":"7","author":"S Bansal","year":"2015","journal-title":"World J Hepatol"},{"key":"ref21","unstructured":"Rapport_Prise_en_charge_Hepatites_2014-DHUMEAUX.pdf [Internet]. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.sante.gouv.fr\/IMG\/pdf\/Rapport_Prise_en_charge_Hepatites_2014.pdf\" xlink:type=\"simple\">http:\/\/www.sante.gouv.fr\/IMG\/pdf\/Rapport_Prise_en_charge_Hepatites_2014.pdf<\/ext-link>"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"e0126920","DOI":"10.1371\/journal.pone.0126920","article-title":"The undiagnosed chronically-infected HCV population in France. Implications for expanded testing recommendations in 2014","volume":"10","author":"C Brouard","year":"2015","journal-title":"PLoS ONE"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"e51194","DOI":"10.1371\/journal.pone.0051194","article-title":"Identification of hidden key hepatitis C populations: an evaluation of screening practices using mixed epidemiological methods","volume":"7","author":"APA Vermeiren","year":"2012","journal-title":"PLoS ONE"},{"key":"ref24","article-title":"Interventions to optimise the care continuum for chronic viral hepatitis: a systematic review and meta-analyses","author":"K Zhou","journal-title":"The Lancet Infectious Diseases"},{"key":"ref25","first-page":"S25","article-title":"[Should hepatitis C be screened? Analysis of oriented screening strategies for hepatitis C virus infection]","volume":"21","author":"JC Desenclos","year":"1997","journal-title":"Gastroenterol Clin Biol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1128\/JCM.43.4.1722-1726.2005","article-title":"Usefulness of the hepatitis C virus core antigen assay for screening of a population undergoing routine medical checkup","volume":"43","author":"C Gaudy","year":"2005","journal-title":"J Clin Microbiol"},{"key":"ref27","unstructured":"Sass et al. InVS | BEH n\u00b014 (4 avril 2006). Le score Epices: un score individuel de pr\u00e9carit\u00e9. Construction du score et mesure des relations avec des donn\u00e9es de sant\u00e9, dans une population de 197 389 personnes. [Internet]. [cited 25 Aug 2015]. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.invs.sante.fr\/beh\/2006\/14\/\" xlink:type=\"simple\">http:\/\/www.invs.sante.fr\/beh\/2006\/14\/<\/ext-link>"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"5532","DOI":"10.3748\/wjg.v12.i34.5532","article-title":"Long-term outcomes of chronic hepatitis C patients with sustained virological response at 6 months after the end of treatment","volume":"12","author":"D Chavalitdhamrong","year":"2006","journal-title":"World J Gastroenterol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"N Afdhal","year":"2014","journal-title":"N Engl J Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0183232","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T18:18:36Z","timestamp":1588961916000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0183232"}},"subtitle":[],"editor":[{"given":"Yury E.","family":"Khudyakov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,8,29]]},"references-count":29,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,8,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0183232","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,29]]}}}